MarketFriction

Perk Pharmaceuticals Ltd

BSE 530673 · Pharmaceuticals
Market cap₹Cr.
Not trading

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011
Sales1.141.421.301.401.321.21
Expenses1.641.141.431.200.810.97
Operating Profit-0.500.28-0.130.200.510.24
OPM %-43.86%19.72%-10.00%14.29%38.64%19.83%
Other Income0.000.000.010.000.000.00
Interest0.040.050.020.030.040.03
Depreciation0.140.130.160.150.140.14
Profit before tax-0.680.10-0.300.020.330.07
Tax %0.00%0.00%0.00%0.00%0.00%0.00%
Net Profit-0.680.10-0.300.020.330.07
EPS in Rs
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%1%-2%-8%
Compounded Profit Growth%16%31%-79%
Stock Price CAGR%%%%
Return on Equity%1%3%1%
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011
Equity Capital6.386.386.386.386.386.38
Reserves-2.61-0.85-1.15-1.13-0.79-0.72
Borrowings0.470.350.460.330.270.02
Other Liabilities1.070.990.850.420.851.40
Total Liabilities5.316.876.546.006.717.08
Fixed Assets2.874.394.174.023.883.82
CWIP0.080.080.100.100.100.10
Investments0.000.000.000.000.000.00
Other Assets2.362.402.271.882.733.16
Total Assets5.316.876.546.006.717.08
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011
Cash from Operating Activity0.020.150.03-0.080.050.58
Cash from Investing Activity-0.03-0.010.030.000.00-0.08
Cash from Financing Activity0.01-0.120.11-0.13-0.05-0.25
Net Cash Flow0.000.020.17-0.210.000.25
Free Cash Flow-0.010.140.06-0.080.050.50
CFO/OP-4%54%-23%-40%10%242%
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011
Debtor Days105.66138.80168.46224.21461.78588.22
Inventory Days471.46849.33385.74418.85730.00556.62
Days Payable117.86224.62153.47149.59343.53766.50
Cash Conversion Cycle459.25763.51400.73493.48848.25378.35
Working Capital Days361.80323.87314.46362.39503.26437.40
ROCE %2.96%-4.84%0.89%6.47%1.73%

Fundamentals

Market Cap₹ Cr.
Current Price₹
Book Value₹
ROCE1.73 %
ROE1.24 %
Dividend Yield%
Face Value₹ 10.0
Compounded Sales Growth (TTM)-8%
Compounded Profit Growth (TTM)-79%
Standalone figures.
Profitability
Operating margin (excl. other income)19.72%
Operating margin (incl. other income)19.72%
EBITDA margin19.72%
Pre-tax margin7.04%
Net profit margin7.04%
ROE2.15%
ROCE2.96%
ROA1.64%
ROIC (approx.)2.60%
Growth
Sales growth (latest year)24.56%
Per share
EPS (TTM)Rs 0.16
EPS (latest year)Rs 0.16
Book value per shareRs 8.66
Sales per shareRs 2.22
Cash flow per shareRs 0.23
Free cash flow per shareRs 0.78
Efficiency
Asset turnover0.21x
Fixed asset turnover0.32x
Inventory turnover0.50x
Inventory days736 days
Debtor days139 days
Debtors turnover2.63x
Creditor days766 days
Cash conversion cycle378 days
Working capital days437 days
Leverage
Total debtRs 0 Cr
Cash and bankRs 0 Cr
Net debtRs 0 Cr
Debt to equity0.06x
Net debt / EBITDA0.86x
Interest coverage3.00x
Owners' fund to total sources80.49%
Debt to assets5.09%
Cash flow
Cash from Operating Activity (latest year)Rs 0 Cr
Cash from Investing Activity (latest year)Rs -0 Cr
Cash from Financing Activity (latest year)Rs -0 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs 0 Cr
FCFE (approx.: FCF + change in debt)Rs 0 Cr
Cash from ops / profit, 5 years3.32x
Sales to cash flow9.47x
Statement figures
Net sales (TTM)Rs 1 Cr
Net sales (latest year)Rs 1 Cr
Operating profit excl. other income (latest year)Rs 0 Cr
EBITDA (TTM)Rs 0 Cr
PBDT (TTM)Rs 0 Cr
Profit before tax (TTM)Rs 0 Cr
Net profit (TTM)Rs 0 Cr
Net profit (latest year)Rs 0 Cr
Depreciation (TTM)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 1 Cr
Total expenditure (latest year)Rs 1 Cr
Total income (latest year)Rs 1 Cr
Share capitalRs 6 Cr
ReservesRs -1 Cr
Shareholders' fundsRs 6 Cr
Total assetsRs 7 Cr
Net blockRs 4 Cr
Capital work in progressRs 0 Cr
ReceivablesRs 1 Cr
InventoryRs 1 Cr
Other liabilitiesRs 1 Cr
Shares outstanding (crore)0.64
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.

Red flags

F-score 7 of 8
explainReceivables outrunning sales Receivables grew 64% vs sales +25% in 2011
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

No quarterly results published.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Perk Pharmaceuticals Ltd?

Perk Pharmaceuticals Ltd (530673) has a market capitalisation of Rs Cr. at the close.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03